NCT06716580Recruiting
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 29 Nov 2024
- Start date
- 1 Apr 2025
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Lung cancer
- NCT number
- NCT06716580
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 1 Apr 2025 to the primary completion date, 1 Sept 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ.
- Personal diagnosis of lung cancer
Age
- Individuals \<40 years of age
Other
- Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period.
- More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use
- Adults unable to provide informed consent
- Prisoners
- Pregnant women
- Not able to be compliant with study requirements
Who the study is looking for
- Non-tobacco using (currently)
- Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
- East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian
- Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino
- Latinx includes those who self-identify as a person of Central or South American and the Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain
- Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
- Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
- Non-tobacco using (currently)
- Self-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:
- Family history of EGFR positive LC L858R or exon 19
- Personal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
- History of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis
- Symptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea
- Excluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, productive cough with green or yellow sputum
- Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
- Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
Age in the registry: 40 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Dana-Farber Cancer Institute at Steward St. Elizabeth's Coordinator of this site? Confirm its status | Brighton | United States | Not yet recruiting |
| Dana-Farber Cancer Instiute Merrimack Valley Coordinator of this site? Confirm its status | Methuen | United States | Not yet recruiting |
| Dana-Farber Cancer Institute South Shore Coordinator of this site? Confirm its status | South Weymouth | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.